U.S. Pharma Industry Analysis
UpdatedJun 07, 2023
DataAggregated Company Financials
Companies322
- 7D3.0%
- 3M7.6%
- 1Y-1.5%
- YTD-3.9%
In the last week, the Pharma industry is up 3.0%, with Eli Lilly up 3.7%. Meanwhile, Bausch Health Companies actually underperformed within the industry, shrinking 11% in the last week. Overall in the last year, the industry is flat. Earnings are forecast to grow by 14% annually.
Industry Valuation and Performance
Has the U.S. Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 07 Jun 2023 | US$1.7t | US$393.0b | US$60.5b | 18.8x | 28.3x | 4.4x |
| Fri, 05 May 2023 | US$1.7t | US$392.9b | US$59.5b | 19.2x | 28.7x | 4.3x |
| Sun, 02 Apr 2023 | US$1.6t | US$401.2b | US$69.5b | 15.1x | 22.7x | 3.9x |
| Tue, 28 Feb 2023 | US$1.6t | US$401.8b | US$68.4b | 17.7x | 22.9x | 3.9x |
| Thu, 26 Jan 2023 | US$1.7t | US$402.6b | US$69.4b | 17.6x | 24.4x | 4.2x |
| Sat, 24 Dec 2022 | US$1.8t | US$403.7b | US$70.7b | 16.8x | 24.8x | 4.4x |
| Mon, 21 Nov 2022 | US$1.7t | US$403.7b | US$70.6b | 14.2x | 24.4x | 4.3x |
| Wed, 19 Oct 2022 | US$1.6t | US$403.0b | US$71.3b | 13.1x | 22.6x | 4x |
| Fri, 16 Sep 2022 | US$1.6t | US$403.0b | US$71.3b | 13.7x | 22.2x | 3.9x |
| Sun, 14 Aug 2022 | US$1.7t | US$403.0b | US$70.5b | 15.1x | 23.4x | 4.1x |
| Tue, 12 Jul 2022 | US$1.7t | US$392.4b | US$65.1b | 22x | 26.2x | 4.3x |
| Thu, 09 Jun 2022 | US$1.7t | US$392.5b | US$64.7b | 22.2x | 26.1x | 4.3x |
| Sat, 07 May 2022 | US$1.6t | US$392.7b | US$62.9b | 20.5x | 25.7x | 4.1x |
| Mon, 04 Apr 2022 | US$1.7t | US$373.8b | US$60.3b | 21.4x | 27.5x | 4.4x |
| Wed, 02 Mar 2022 | US$1.5t | US$374.2b | US$60.1b | 21x | 25.2x | 4.1x |
| Fri, 28 Jan 2022 | US$1.6t | US$363.7b | US$40.7b | 21.6x | 38.4x | 4.3x |
| Sun, 26 Dec 2021 | US$1.7t | US$361.1b | US$37.9b | 22.6x | 43.7x | 4.6x |
| Tue, 23 Nov 2021 | US$1.6t | US$360.7b | US$38.2b | 23.5x | 41.3x | 4.4x |
| Thu, 21 Oct 2021 | US$1.5t | US$340.0b | US$24.9b | 21.3x | 61.1x | 4.5x |
| Sat, 18 Sep 2021 | US$1.5t | US$337.6b | US$25.9b | 22.9x | 57.7x | 4.4x |
| Mon, 16 Aug 2021 | US$1.6t | US$338.5b | US$25.8b | 21x | 62.7x | 4.8x |
| Mon, 31 May 2021 | US$1.5t | US$323.4b | US$21.4b | 20.5x | 68.9x | 4.6x |
| Thu, 04 Mar 2021 | US$1.4t | US$304.8b | US$15.6b | 24x | 88.9x | 4.5x |
| Sun, 06 Dec 2020 | US$1.3t | US$284.8b | US$25.5b | 20.6x | 51.2x | 4.6x |
| Wed, 09 Sep 2020 | US$1.3t | US$279.3b | US$31.3b | 24.9x | 41.9x | 4.7x |
Price to Earnings Ratio
39.3x
Current Industry PE
- Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 28.3x which is lower than its 3-year average PE of 43.6x.
- The industry is trading close to its 3-year average PS ratio of 4.4x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have grown 25% per year over the last three years.
- Revenues for these companies have grown 12% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Comparison
How does U.S. Pharma compare with similar industries?
| US Market | 2.47% | |
| Healthcare | 2.89% | |
| Pharma | 2.98% | |
| Pharma | 2.98% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| JNJ Johnson & Johnson | US$158.52 | 2.2% +US$9.7b | -10.6% | PE34.9x | |
| LLY Eli Lilly | US$436.37 | 1.6% +US$6.6b | 39.2% | PE72.8x | |
| PFE Pfizer | US$38.89 | 2.3% +US$4.9b | -27.3% | PE7.6x | |
| BMY Bristol-Myers Squibb | US$65.16 | 1.1% +US$1.5b | -14.5% | PE18.7x | |
| VTRS Viatris | US$9.71 | 6.1% +US$671.5m | -18.1% | PE6.1x |